Replies to post #657528 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Yes, nWBO owns EDEN outright and Advent will as their CDMO in their factory, be necessarily involved in implementation. The company does not need to “license” the systems out and I don’t think that would be wise nor necessary for them to do in any instance at this time. It’s a critical process invention that gives the company basically a core technology of y to protect DCVax-L and its manufacture for many more years after other patents expire and depending on how they want to commercialize, maintaining their control and advantage is key. This is where I have and always will disagree with you Gary, there are not “desktop printers”, they won’t become and OEM selling these machines to hospitals to make their own concoctions, that is not this business and if they wanted to be in that business, they could have been selling the machines generically for years with Advent’s and Flaskworks subcontracting implementation for anyone that wanted. That is not the business they are in and I doubt very much they would get more than a few million out of it and with costs, I think it would be a loser. Hence why Flaskworks could be bought so inexpensively.

At this time, implementing Flaskworks will be useful and key for ensuring they have a competitive advantage. It is not absolutely necessary for them to get commercially licensed. But once implemented it will make them far more commercially viable and attractive as a venture. Of course they already have an amazing treatment for which they will presumably have set prices that not only makes NWBO viable but also a fully sustainable entity that can fund itself from operations going forward, become a general cancer vaccine company, also develop DCVax Direct and potentially perhaps develop other new products to ultimately become a major in Oncology. Or be acquired, which is also possible, and one would want to see them acquired at a fair price for what they have developed, so it is still important that their commercialization plan be viewed favorably by that big pharma partner.